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Abstract Sialidosis is a lysosomal storage disease caused by the
deficiency of K-N-acetylneuraminidase (NEU1; sialidase), the
key enzyme for the intralysosomal catabolism of sialylated
glycoconjugates. We have identified a homozygous transversion
in the last intron (IVSE +1 GsC) in neu1 of a sialidosis patient.
Sequencing of the truncated cDNA revealed an alternatively
spliced neu1 transcript which lacks the complete sequence of
exon 5. Skipping of exon 5 leads to a frameshift and results in a
premature termination codon. This is the first description of an
intronic point mutation causing a complete deficiency of the
lysosomal neuraminidase activity. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The catabolism of sialylated glycoconjugates is strictly de-
pendent on the function of speci¢c hydrolases, which occur in
viruses, bacteria, protozoa, birds and mammals [1^3]. Among
these exoglycosidases are members of a family of neuramini-
dases or sialidases that catalyze the cleavage of K-glycosidi-
cally linked terminal N-acetylneuraminic acid (sialic acid)
from glycoconjugates [4]. The intralysosomal N-acetyl-K-neur-
aminidase (NEU1) in mammals, unlike the membrane-bound
and cytosolic neuraminidases, is catalytically active only when
it is bound to a carboxypeptidase called protective protein/
cathepsin A (PPCA) in a multi-protein complex that also con-
tains L-galactosidase (GAL) and N-acetylgalactosamine-6-sul-
fate sulfatase [5^10]. Genetically based alterations of constit-
uents of this complex result in lysosomal storage diseases such
as sialidosis and galactosialidosis. Sialidosis is due to lesions
in the neu1 gene located on chromosome 6p21.3 [11] and is
characterized biochemically by the de¢ciency of lysosomal
neuraminidase activity and an abnormal tissue accumulation
and urinary excretion of sialic acid-containing compounds
(for review see [12]). According to the clinical symptoms, sia-
lidosis has been divided into two subtypes with di¡erent ages
of onset and severity. Sialidosis type I, also called non-dys-
morphic type, is the mild form of the disease with late onset,
bilateral macular cherry-red spots, progressively impaired vi-
sion and myoclonus syndrome. The type II or dysmorphic
type with infantile onset is characterized by skeletal dysplasia,
Hurler-like phenotype, dystosis multiplex, mental retardation
and hepatosplenomegaly. The severe form often occurs pre-
natally and manifests itself by ascites and hydrops fetalis [13].
Galactosialidosis is associated with primary genetic defects of
PPCA causing a disruption of the complex resulting in a
combined de¢ciency of GAL and neuraminidase activities
(for review see [14]).
Since the cloning of the neu1 mRNA [11,15], several studies
have reported the identi¢cation of genetic alterations in neu1
of unrelated sialidosis patients. The majority of reported mu-
tations consist of missense mutation (15 cases), followed by
nonsense mutations (four cases), two insertions and two dele-
tions [11,15^19]. All mutations are exonic and distributed over
the entire coding region of neu1. Recent work using 3D mod-
eling of mutated protein sequences indicates that even amino
acid changes which do not interfere with structurally impor-
tant domains have a strong in£uence on enzyme activity as
residues located in speci¢c regions on the surface of the en-
zyme may be involved in functionally important protein in-
teractions [20].
In order to identify novel mutations within the neu1 gene,
we performed a sequencing-based screening of cultured skin
¢broblast derived from sialidosis patients. In the present pa-
tient with the severe type II, we found a homozygous
g2736GsC transversion (IVSE +1 GsC) located in the splice
donor site of intron E causing skipping of exon 5 and com-
plete loss of lysosomal neuraminidase activity.
2. Materials and methods
2.1. Clinical data
The patient was a full-term small-for-date female newborn delivered
by Cesarean section at week 41 of pregnancy (weight: 2740 g, length:
43 cm, circumference of the head: 31 cm). She was the ¢rst child of
healthy parents without any known consanguinity. At week 27 of
pregnancy, hydrops fetalis was detected by sonography. After a
pathological cardiotocogram, birth was initiated by Cesarean section.
Pre- and postnatally, the patient su¡ered from ascites and edema. In
sonographic examinations of the brain ¢ne calci¢cations of the thala-
mic striatum blood vessels were seen. Besides this, symmetrical and
synchronic myoclonus of the extremities lasting several minutes was
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observed. The hemogram and further parameters were inconspicuous.
The analysis of chromosomes was normal (46XX).
2.2. Tissue culture
Skin ¢broblasts derived from the patient and healthy donors were
cultured in Eagle’s minimum essential medium supplemented with
10% fetal calf serum (Life Technologies, USA) and non-essential ami-
no acids as described previously [21].
2.3. Enzyme activity assays
Enzyme activity of the lysosomal neuraminidase was determined
using 2P,4-methylumbelliferyl-K-N-acetylneuraminic acid as substrate
according to Harzer et al. [22]. The GAL activity was measured ac-
cording to Gehler et al. [23].
2.4. Isolation of genomic DNA and total RNA
Genomic DNA and total RNA were isolated from cultured skin
¢broblasts derived from the patient and healthy donors using the
QIAamp DNA Mini kit and the RNeasy kit (Qiagen, Germany).
1 Wg of DNase I (Roche Diagnostics GmbH, Germany)-treated total
RNA was reverse transcribed by oligo(dT) and random hexamer
priming using the SuperScript II reverse transcriptase (Life Technol-
ogies, USA).
2.5. neu1 mRNA expression
Semi-quantitative RT-PCR following oligo(dT)-primed reverse
transcription was used to assess the neu1 transcript level in the siali-
dosis patient. PCR was carried out for 25 cycles using 5P-CCC AAG
CTT AGA TCT TGG AGT CTA GCT GCC AGG GT-3P and 5P-
CCA GGG GCA AAC ACT TCA GT-3P for neu1-speci¢c ampli¢ca-
tion and for 19 cycles using 5P-GAT GCT GGC GCT GAG TAC
GTC-3P and 5P-CGT TGT CAT ACC AGG AAA TGA GC-3P for
GAPDH-speci¢c ampli¢cation. PCR was performed with 2 Wl of the
reverse transcription samples in a total volume of 50 Wl using the hot
start method for both target sequences. Denaturation was done at
94.5‡C for 45 s, annealing at 60‡C for 90 s, primer extension at
72‡C for 150 s and ¢nal extension for 10 min. Ampli¢cation products
were visualized on an ethidium bromide-stained 2% agarose gel and
documented by digitalization (Gel documentation system, Herolab
GmbH, Germany). Signal intensities were quantitated by densitome-
try using the LabImage 2.51 program (Labsoft Diagnostics AG, Ger-
many). The resulting values of the neu1-speci¢c fragments were nor-
malized with GAPDH as internal standard and the result of the
sialidosis patient was displayed as a relative change compared to
the mean of three control donors.
2.6. PCR ampli¢cation and direct sequencing
Genomic DNA was ampli¢ed with exon-speci¢c sets of oligonucleo-
tides as described previously [16]. To amplify intron sequences, PCR
of genomic DNA was carried out with combinations of these exon-
speci¢c oligonucleotides. Ampli¢cation of cDNA was performed with
three overlapping sets of oligonucleotides, which encompassed the
entire coding region of the human lysosomal neuraminidase mRNA
[15]. Ampli¢cation products were separated on 1% agarose gels to
con¢rm the expected length. After puri¢cation, PCR fragments were
sequenced directly in the forward and reverse directions on an Ap-
plied Biosystems 377-18 DNA sequencer using the Big Dye Termina-
tion kit (Applied Biosystems, USA) and the corresponding oligonu-
cleotides.
3. Results
The enzymatic activities of lysosomal neuraminidase and
GAL of ¢broblasts derived from the sialidosis patient were
compared to the activities of healthy donors. The patient’s
¢broblasts exhibited no detectable neuraminidase activity,
whereas that of GAL was normal, establishing the biochem-
ical diagnosis of sialidosis.
The transcriptional activity of neu1 was investigated by
semi-quantitative RT-PCR. The neu1-speci¢c PCR fragments
representing nucleotide positions ca. 355 to +741 of the pa-
tient and healthy control donors were normalized to GAPDH
amplicons. Compared to control donors the sialidosis patient
showed a normal amount of neu1 mRNA.
In order to identify mutations which could form the basis
Fig. 1. Splice donor site mutation in the sialidosis patient. A: The
wild-type (WT) genomic DNA sequence is shown above the pa-
tient’s sequence. The homozygous IVSE +1 GsC transversion is
marked by an arrow in the chromatogram. B: The scheme displays
the localization of the detected mutation in the neu1 genomic se-
quence.
Fig. 2. RT-PCR and cDNA sequencing of the truncated ampli¢ca-
tion product of the sialidosis patient. A: Total RNAs were isolated
from three control donors (Con.) and the sialidosis patient (Pat.),
reverse-transcribed, and PCR performed to generate the indicated
fragment. B: Sequencing of the truncated RT-PCR product (345
bp) detected in the sialidosis patient revealed the complete loss of
exon 5. Amino acid positions altered consecutive to the reading
frame shift are indicated by asterisks.
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for the complete de¢ciency of the NEU1 activity we isolated
genomic DNA from patient’s skin ¢broblasts. Subsequent to
ampli¢cation of the six exons and the ¢ve intervening introns
(A^E) the PCR products were directly sequenced using the
corresponding oligonucleotides. As shown in Fig. 1, there
was a homozygous g2736GsC transversion in the PCR frag-
ment encompassing the 3P region of exon 5, the intervening
intron E and exon 6. The mutation a¡ected the +1 position
within the donor splice site of intron E (IVSE +1 GsC).
RT-PCR ampli¢cation of total RNA isolated from skin
¢broblasts of three unrelated healthy donors generated a
568-bp fragment corresponding to cDNA positions 721^
1288 (Fig. 2A). As con¢rmed by direct DNA sequencing,
the products contained part of exon 4 and the complete se-
quences of exon 5 and exon 6. RT-PCR performed under the
same conditions with total RNA from skin ¢broblasts of the
sialidosis patient produced exclusively a 345-bp fragment. Di-
rect sequencing of this truncated cDNA fragment revealed the
complete deletion of exon 5 (Fig. 2B). Skipping of exon 5 will
result in a frame shift and a premature termination at amino
acid position 268.
4. Discussion
To date, 23 genetic alterations were detected in the lysoso-
mal neuraminidase gene of sialidosis patients. They all were
observed throughout the entire coding region without any
indications for a hot spot region [11,15^19]. Recent studies
using 3D modeling of the mutated sequences were helpful in
understanding the potential in£uence of amino acid substitu-
tions on tertiary protein structure. The majority of mutations
consisted of missense mutations a¡ecting amino acid positions
that were not located within important functional domains
such as the active site or the central core of the molecule. It
was therefore suggested that the position of some of the af-
fected residues on the surface of the enzyme would be critical
for the correct association of NEU1 with the multi-protein
complex that is necessary for catalytic function [20]. In other
cases, the de¢ciency of the enzyme activity could be explained
by nonsense mutations, small insertions or deletions that
cause a shift in the reading frame resulting in a premature
termination codon.
In this study, we have identi¢ed the ¢rst intronic mutations
in the neu1 gene of a patient diagnosed as having sialidosis
type II. The mutated position +1 in intron E (IVSE +1 GsC)
is part of the highly conserved 5P splice donor site. Three
di¡erent consequences could be expected for a splice site mu-
tation, viz. skipping of the entire preceding exon, read-
through of the retained intron, or use of a cryptic splice donor
site. Exon skipping is the most frequently observed result of a
splice site mutation in humans [24] and mammals [25], be-
cause intron inclusion or the use of a cryptic splice site instead
of the destroyed consensus splice site depends on speci¢c se-
quence properties. Retention of an intron may be favored if
the size of the intron does not yield a rede¢ned exon of more
than 300 bp [26]. This is unlikely for the case reported here
because the rede¢ned exon would exceed the limiting size of
300 bp. Recognition of the donor splice site by the U1 small
nuclear ribonucleoprotein particle is the initial step in forma-
tion of the spliceosome and essential for further processing of
the pre-mRNA transcript during the splicing procedure [27].
If no acceptable cryptic splice donor site is recognized in the
vicinity of the authentic splice site, exon skipping seems to
occur [25]. Obviously, no suitable cryptic site could be found
for the mutated splice donor site of intron E, since exon 5 was
completely absent from the mature neu1 transcript of the sia-
lidosis patient.
As the junction between exon 5 and exon 6 of neu1 is not in
frame (the last base of exon 5 and the ¢rst two bases of exon 6
make up codon 341), this frame shift led to a premature
termination codon at position 268 in the aberrantly spliced
mRNA. As shown in Fig. 3, the deduced polypeptide exhibits
a truncation of 148 amino acids at the C-terminus. The com-
plete enzyme de¢ciency can thus be explained by the fact that
the lost C-terminal region of NEU1 contains two of ¢ve struc-
turally important Asp boxes and four of ¢ve strictly conserved
active site residues.
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